Mode
Text Size
Log in / Sign up
N/A N=358 Randomized Double-blind Treatment

Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia

Critical Lower Limb Ischemia

Enrolled (actual)
358
Serious AEs
80.7%
Results posted
Oct 2014
Primary outcome: Primary: Late Lumen Loss (LLL) of the Target Lesion by Quantitative Vascular Angiography (QVA) — 0.605; 0.616 mm

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
IN.PACT Amphirion (Device); Standard PTA (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Medtronic Endovascular
Primary completion
Aug 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Late Lumen Loss (LLL) of the Target Lesion by Quantitative Vascular Angiography (QVA)
0.605; 0.616
PRIMARY
Clinically Driven Target Lesion Revascularization (TLR) of the Target Lesion in the Amputation Free Surviving Patients
9.2; 13.1
PRIMARY
Composite of All Cause Death, Major Amputation and Clinically Driven Target Lesion Revascularization (CD-TLR)
17.67; 15.79
SECONDARY
Amputation Free Survival
81.1; 89.2
SECONDARY
Rate of Wound Healing
73.8; 76.9
SECONDARY
Amputation Free Survival and Wound Healing
58.7; 68.0
SECONDARY
Amputation Free Survival and Resolved Critical Limb Ischemia (CLI)
57.1; 66.0
SECONDARY
Death, Amputation and Clinically Driven Target Lesion Revascularization (TLR)
39.6; 34.2
SECONDARY
Primary Sustained Clinical Improvement
69.3; 68.1
SECONDARY
Secondary Sustained Clinical Improvement
73.6; 78.0
SECONDARY
Quality of Life Assessment by EQ5D
0.6975; 0.7445
SECONDARY
Walking Capacity Assessment
74.6; 75.4
SECONDARY
MAE (Major Adverse Events)
35.2; 25.2
SECONDARY
Device Success
98.0; 96.3
SECONDARY
Technical Success
93.2; 88.4
SECONDARY
Procedural Success
98.3; 100
SECONDARY
Days of Hospitalization
4.5; 4.0
SECONDARY
Improvement % Diameter Stenosis (%DS) of the Target Leasion (TL) Assessed by Quantitative Vascular Angiography (QVA)
82.0; 71.0

Summary

This is a prospective, multi-center, randomized (2:1) trial of symptomatic patients with critical limb ischemia (CLI) secondary to atherosclerotic lesions (stenotic or occluded) of the infrapopliteal vessels. Patients will undergo a percutaneous transluminal endovascular procedure with either the IN.PACT Amphirion™ drug eluting balloon or with a standard (Percutaneous Transluminal Angioplasty) PTA balloon. Patients will be followed with pre-study, post-study, and follow-up evaluations.

Eligibility Criteria

Inclusion Criteria

General Inclusion Criteria

  • Age ≥18 years and ≤85 years
  • Patient or patient's legal representative have been informed of the nature of the study, agrees to participate and has signed an Ethical Committee approved consent form
  • Female patients of childbearing potential have a negative pregnancy test ≤7 days before the procedure and are willing to use a reliable method of birth control for the duration of study participation
  • Patient has documented chronic Critical Limb Ischemia (CLI) in the target limb prior to the study procedure with Rutherford Category 4, 5 or 6
  • Life expectancy >1 year in the Investigator's opinion

General Angiographic Inclusion Criteria

  • Reference vessel(s) diameter between 2 and 4 mm
  • Single or multiple lesions with ≥70% diameter stenosis (DS) of different lengths in one or more main afferent crural vessels including the tibioperoneal trunk
  • At least one non occluded crural vessel with angiographically documented run-off to the foot either direct or through collaterals

Angiographic Inclusion Criteria for Late Lumen Loss (LLL) assessment

  • Angio-target lesion (TL) is one identifiable single solitary or series of multiple adjacent lesions with a diameter stenosis (DS) ≥70% and a cumulative length ≤100 mm that can be covered by a single IN.PACT Amphirion™ (10 mm balloon landing zone in both edges is mandatory)
  • Angio-target lesion (TL) is the only lesion in that vessel (only one Angio-TL per patient is allowed)

Exclusion Criteria

General Exclusion Criteria

  • Patient unwilling or unlikely to comply with Follow-Up schedule
  • Planned major index limb amputation

General Angiographic Exclusion Criteria

  • Lesion and / or occlusions located or extending in the popliteal artery or below the ankle joint space
  • Inflow lesion or occlusion in the ipsilateral Iliac, Superficial Femoral Artery (SFA), popliteal arteries with length ≥15 cm
  • Significant (≥50% DS) inflow lesion or occlusion in the ipsilateral Iliac, Superficial Femoral Artery (SFA) and popliteal arteries left untreated
  • Previously implanted stent in the target lesions(s)
  • Aneurysm in the target vessel
  • Acute thrombus in the target limb

General Procedural Exclusion Criteria

  • Failure to obtain a <30% residual stenosis in pre-existing, hemodynamically significant (≥50% diameter stenosis (DS) and <15 cm length) inflow lesions in the ipsilateral iliac, SFA and popliteal artery. No Drug Eluting Stents (DES) and / or Drug Eluting Balloon (DEB) allowed for the treatment of inflow lesions.
  • Failure to cross the TL with a 0.014" guide wire
  • Use of alternative therapy, e.g. atherectomy, cutting balloon, laser, radiation therapy, DES as part of the index procedure

ANGIOGRAPHIC cohort General Exclusion Criteria:

  • Glomerular Filtration Rate (GFR) <30 ml/min except for patients with renal end stage disease on chronic haemodialysis
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00941733). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search